Education
About Us
Working with TipRanks
Follow Us
OncoArendi Therapeutics SA (PL:MOC)
:MOC
Total Valuation
OncoArendi Therapeutics SA has a market cap or net worth of zł153.29M. The enterprise value is zł134.97M.
Market Capzł153.29M
Enterprise Valuezł134.97M
Share Statistics
OncoArendi Therapeutics SA has 20,603,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,603,155
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoArendi Therapeutics SA’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -29.75%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-29.75%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee28.62K
Profits Per Employee-306.74K
Employee Count102
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OncoArendi Therapeutics SA is ―. OncoArendi Therapeutics SA’s PEG ratio is 0.79.
PE Ratio―
PS Ratio69.90
PB Ratio1.97
Price to Fair Value1.97
Price to FCF-2.53
Price to Operating Cash Flow-2.76
PEG Ratio0.79
Income Statement
In the last 12 months, OncoArendi Therapeutics SA had revenue of 2.92M and earned -31.29M in profits. Earnings per share was -1.55.
Revenue2.92M
Gross Profit-489.91K
Operating Income-33.61M
Pretax Income-31.29M
Net Income-31.29M
EBITDA-27.37M
Earnings Per Share (EPS)-1.55
Cash Flow
In the last 12 months, operating cash flow was -51.20M and capital expenditures -9.11M, giving a free cash flow of -60.32M billion.
Operating Cash Flow-51.20M
Free Cash Flow-60.32M
Free Cash Flow per Share-2.93
Dividends & Yields
OncoArendi Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-19.31%
50-Day Moving Average6.59
200-Day Moving Average7.13
Relative Strength Index (RSI)67.53
Average Volume (3m)22.76K
Important Dates
OncoArendi Therapeutics SA upcoming earnings date is Apr 7, 2026, Before Open (Confirmed).
Last Earnings DateOct 31, 2025
Next Earnings DateApr 7, 2026
Ex-Dividend Date―
Financial Position
OncoArendi Therapeutics SA as a current ratio of 9.82, with Debt / Equity ratio of 6.24%
Current Ratio9.82
Quick Ratio9.82
Debt to Market Cap0.01
Net Debt to EBITDA0.40
Interest Coverage Ratio-356.66
Taxes
In the past 12 months, OncoArendi Therapeutics SA has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OncoArendi Therapeutics SA EV to EBITDA ratio is -7.05, with an EV/FCF ratio of -2.39.
EV to Sales66.15
EV to EBITDA-7.05
EV to Free Cash Flow-2.39
EV to Operating Cash Flow-3.39
Balance Sheet
OncoArendi Therapeutics SA has zł22.46M in cash and marketable securities with zł5.58M in debt, giving a net cash position of zł16.88M billion.
Cash & Marketable Securitieszł22.46M
Total Debtzł5.58M
Net Cashzł16.88M
Net Cash Per Sharezł0.82
Tangible Book Value Per Sharezł2.45
Margins
Gross margin is 29.53%, with operating margin of -1151.35%, and net profit margin of -1071.83%.
Gross Margin29.53%
Operating Margin-1151.35%
Pretax Margin-1071.83%
Net Profit Margin-1071.83%
EBITDA Margin-937.75%
EBIT Margin-1068.61%
Analyst Forecast
The average price target for OncoArendi Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―